Serotonin modulates anxiety-like behaviors during withdrawal from adolescent anabolic-androgenic steroid exposure in Syrian hamsters

Hormones and Behavior

Volumn 62, Issue 5, 2012, Pages 569-578

  Ricci, Lesley A ^a   Morrison, Thomas R ^a   Melloni, Richard H ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Adolescence; Anabolic androgenic steroids; Anxiety; Fluoxetine; Serotonin

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROSTANOLONE; DIHYDROTESTOSTERONE UNDECYCLATE; FLUOXETINE; NANDROLONE; SEROTONIN; TESTOSTERONE CIPIONATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ANXIETY DISORDER; ARTICLE; BRAIN REGION; CENTRAL NUCLEUS (AMYGDALA); CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELEVATED PLUS MAZE TEST; FRONTAL CORTEX; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LATERAL SEPTUM; LIGHT DARK CYCLE; LOW DRUG DOSE; MALE; MEDIAL AMYGDALA; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SEED FINDING TEST; SIGNAL TRANSDUCTION; SYRIAN HAMSTER;

AGE FACTORS; AGGRESSION; ANABOLIC AGENTS; ANDROGENS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CRICETINAE; DISEASE MODELS, ANIMAL; MALE; MESOCRICETUS; MODELS, BIOLOGICAL; SEROTONIN; STEROIDS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84868205301     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2012.09.007     Document Type: Article

References (103)

1. Agis-Balboa R.C., Pibiri F., Nelson M., Pinna G. Enhanced fear responses in mice treated with anabolic androgenic steroids. Neuroreport 2009, 20:617-621.
2. Aikey J.L., Nyby J.G., Anmuth D.M., James P.J. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm. Behav. 2002, 42:448-460.
3. Ambar G., Chiavegatto S. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice. Genes Brain Behav. 2009, 8:161-173.
4. Apter A., van Praag H.M., Plutchik R., Sevy S., Korn M., Brown S.L. Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster?. Psychiatry Res. 1990, 32:191-199.
5. Bahrke M.S., Yesalis C.E., Wright J.E. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. A review. Sports Med. 1990, 10:303-337.
6. Ballenger J.C., Wheadon D.E., Steiner M., Bushnell W., Gergel I.P. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry 1998, 155:36-42.
7. Bing O., Heilig M., Kakoulidis P., Sundblad C., Wiklund L., Eriksson E. High doses of testosterone increase anticonflict behaviour in rat. Eur. Neuropsychopharmacol. 1998, 8:321-323.
8. Bitran D., Kellogg C.K., Hilvers R.J. Treatment with an anabolic-androgenic steroid affects anxiety-related behavior and alters the sensitivity of cortical GABAA receptors in the rat. Horm. Behav. 1993, 27:568-583.
9. Blomhoff S., Haug T.T., Hellstrom K., Holme I., Humble M., Madsbu H.P., Wold J.E. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br. J. Psychiatry 2001, 179:23-30.
10. Bourin M., Hascoet M. The mouse light/dark box test. Eur. J. Pharmacol. 2003, 463:55-65.
11. Brower K.J. Anabolic steroids; addictive, psychiatric and medical consequences. Am. J. Addict. 1992, 1:100-114.
12. Brower K.J. Anabolic steroid abuse and dependence. Curr. Psychiatry Rep. 2002, 4:377-387.
13. Carli M., Prontera C., Samanin R. Effect of 5-HT1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity. Neuropharmacology 1989, 28:471-476.
14. Carrillo M., Ricci L.A., Melloni R.H. Developmental and withdrawal effects of adolescent AAS exposure on the glutamatergic system in hamsters. Behav. Neurosci. 2011, 125:452-464.
15. Clark M.S., Neumaier J.F. The 5-HT1B receptor: behavioral implications. Psychopharmacol. Bull. 2001, 35:170-185.
16. Collinson N., Dawson G.R. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology (Berl) 1997, 132:35-43.
17. Corrigan B. Anabolic steroids and the mind. Med. J. Aust. 1996, 165:222-226.
18. Cowen P.J. Serotonin receptor subtypes: implications for psychopharmacology. Br. J. Psychiatry Suppl. 1991, 7-14.
19. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 1980, 13:167-170.
20. Critchley M.A., Handley S.L. Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 1987, 93:502-506.
21. Daly R.C., Su T.P., Schmidt P.J., Pagliaro M., Pickar D., Rubinow D.R. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology 2003, 28:317-331.
22. Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., Zhao N., Connor K.M., Lynch T.R., Gadde K.M. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch. Gen. Psychiatry 2004, 61:1005-1013.
23. Deakin J. The role of serotonin in depression and anxiety. Eur. Psychiatry 1998, 13(Suppl. 2):57s-63s.
24. Deakin J.F. The role of serotonin in panic, anxiety and depression. Int. Clin. Psychopharmacol. 1998, 13(Suppl. 4):S1-S5.
25. DeLeon K.R., Grimes J.M., Connor D.F., Melloni R.H. Adolescent cocaine exposure and offensive aggression: involvement of serotonin neural signaling and innervation in male Syrian hamsters. Behav. Brain Res. 2002, 133:211-220.
26. Delville Y., Mansour K.M., Ferris C.F. Serotonin blocks vasopressin-facilitated offensive aggression: interactions within the ventrolateral hypothalamus of golden hamsters. Physiol. Behav. 1996, 59:813-816.
27. Delville Y., Melloni R.H., Ferris C.F. Behavioral and neurobiological consequences of social subjugation during puberty in golden hamsters. J. Neurosci. 1998, 18:2667-2672.
28. Delville Y., De Vries G.J., Ferris C.F. Neural connections of the anterior hypothalamus and agonistic behavior in golden hamsters. Brain Behav. Evol. 2000, 55:53-76.
29. Dunlop B.W., Davis P.G. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim. Care Companion J. Clin. Psychiatry 2008, 10:222-228.
30. Ernst M., Fudge J.L. A developmental neurobiological model of motivated behavior: anatomy, connectivity and ontogeny of the triadic nodes. Neurosci. Biobehav. Rev. 2009, 33:367-382.
31. Fehon D.C., Grilo C.M., Lipschitz D.S. Correlates of community violence exposure in hospitalized adolescents. Compr. Psychiatry 2001, 42:283-290.
32. Fernandez-Guasti A., Martinez-Mota L. Anxiolytic-like actions of testosterone in the burying behavior test: role of androgen and GABA-benzodiazepine receptors. Psychoneuroendocrinology 2005, 30:762-770.
33. Ferris C.F. Adolescent stress and neural plasticity in hamsters: a vasopressin-serotonin model of inappropriate aggressive behaviour. Exp. Physiol. 2000, (85 Spec No):85S-90S.
34. Ferris C.F., Delville Y. Vasopressin and serotonin interactions in the control of agonistic behavior. Psychoneuroendocrinology 1994, 19:593-601.
35. Ferris C.F., Melloni R.H., Koppel G., Perry K.W., Fuller R.W., Delville Y. Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. J. Neurosci. 1997, 17:4331-4340.
36. File S.E. The effects of neonatal administration of clonazepam on passive avoidance and on social, aggressive and exploratory behavior of adolescent male rats. Neurobehav. Toxicol. Teratol. 1986, 8:447-452.
37. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 2001, 125:151-157.
38. Floody O.R., Pfaff D.W. Aggressive behavior in female hamsters: the hormonal basis for fluctuations in female aggressiveness correlated with estrous state. J. Comp. Physiol. Psychol. 1977, 91:443-464.
39. Frye C.A., Seliga A.M. Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats. Cogn. Affect. Behav. Neurosci. 2001, 1:371-381.
40. Goodman W.K., Bose A., Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. 2005, 87:161-167.
41. Graeff F.G., Guimaraes F.S., De Andrade T.G., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 1996, 54:129-141.
42. Grimes J.M., Melloni R.H. Serotonin modulates offensive attack in adolescent anabolic steroid-treated hamsters. Pharmacol. Biochem. Behav. 2002, 73:713-721.
43. Grimes J.M., Melloni R.H.J. Prolonged alterations in the serotonin neural system following the cessation of adolescent anabolic-androgenic steroid exposure in hamsters (Mesocricetus auratus). Behav. Neurosci. 2006, 120:1242-1251.
44. Grimes J.M., Ricci L.A., Melloni R.H. Plasticity in anterior hypothalamic vasopressin correlates with aggression during anabolic/androgenic steroid withdrawal. Behav. Neurosci. 2006, 120:115-124.
45. Grimes J.M., Ricci L.A., Melloni R.H. Alterations in anterior hypothalamic vasopressin, but not serotonin, correlate with the temporal onset of aggressive behavior during adolescent anabolic-steroid exposure in hamsters. Behav. Neurosci. 2007, 121:941-948.
46. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., Santarelli L., Beck S., Hen R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400.
47. Guillot P.V., Chapouthier G. Intermale aggression and dark/light preference in ten inbred mouse strains. Behav. Brain Res. 1996, 77:211-213.
48. Hall R.C.W., Hall R.C.W., Chapman M.J. Psychiatric complications of anabolic steroid abuse. Psychosomatics 2005, 46:285-290.
49. Harrison R.J., Connor D.F., Nowak C., Nash K., Melloni R.H. Chronic anabolic-androgenic steroid treatment during adolescence increases anterior hypothalamic vasopressin and aggression in intact hamsters. Psychoneuroendocrinology 2000, 25:317-338.
50. Hascoet M., Bourin M., Dhonnchadha B.A. The mouse light-dark paradigm: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:141-166.
51. Holmes A., Yang R.J., Lesch K.P., Crawley J.N., Murphy D.L. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 2003, 28:2077-2088.
52. Johnson M.D. Anabolic steroid use in adolescent athletes. Pediatr. Clin. North Am. 1990, 37:1111-1123.
53. Kanayama G., Hudson J.I., Pope H.G. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend. 2008, 98:1-12.
54. Kashkin K.B., Kleber H.D. Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA 1989, 262:3166-3170.
55. Kasper S., Stein D.J., Loft H., Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry 2005, 186:222-226.
56. Kennett G.A., Dourish C.T., Curzon G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur. J. Pharmacol. 1987, 134:265-274.
57. King J.A., Ferris C.F., Messenger T. Seed finding in golden hamsters: a potential animal model for the screening of anxiolytic drugs. Neuropsychobiology 2002, 45:150-155.
58. Koukoulas I., Webb G.C., Bottema C.D., Gill C., Johnston C.I., Aldred G.P. Genomic characterization of the sheep vasopressin V1a receptor gene and promoter, with assignment to bands q23-24 of sheep chromosome 3 and cattle chromosome 5. Gene 1999, 240:183-192.
59. Kusserow H., Davies B., Hortnagl H., Voigt I., Stroh T., Bert B., Deng D.R., Fink H., Veh R.W., Theuring F. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. Brain Res. Mol. Brain Res. 2004, 129:104-116.
60. Lerwill C.J., Makings P. The agonistic behavior of the golden hamster. Anim. Behav. 1971, 19:714-721.
61. Lesch K.P. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 1991, 15:723-733.
62. Lindqvist A.-S., Eriksson B., Ehrnborg C., Fahlke C., Moberg T., Rosen T. AAS abuse in former competitive sport athletes. First Nordic Conference on Abuse of Anabolic Steroids and Anti-doping Work, Uppsala, Sweden 2007.
63. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
64. Malone D.A., Dimeff R.J. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J. Clin. Psychiatry 1992, 53:130-132.
65. Malone D.A., Dimeff R.J., Lombardo J.A., Sample R.H. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin. J. Sport Med. 1995, 5:25-31.
66. McIntosh, A., Cohn, A., Turnbull, N., Esmonde, L., Dennis, P., Eatock, J., Feetam, C., Hague, J., Hughes, I., Kelly, J., Kosky, N., Lear, G., Ratcliffe, J., Salkovskis, P., 2004. Clinical guidelines and evidence review for panic disorder and generalized anxiety disorder. Vol., ed.^eds. University of Sheffield/London: National Collaborating Centre for Primary Care, Sheffield.
67. Melloni R.H., Ricci L.A. Adolescent exposure to anabolic/androgenic steroids and the neurobiology of offensive aggression: a hypothalamic neural model based on findings in pubertal Syrian hamsters. Horm. Behav. 2010, 58:177-191.
68. Michelson D., Allgulander C., Dantendorfer K., Knezevic A., Maierhofer D., Micev V., Paunovic V.R., Timotijevic I., Sarkar N., Skoglund L., Pemberton S.C. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br. J. Psychiatry 2001, 179:514-518.
69. Minkin D.M., Meyer M.E., van Haaren F. Behavioral effects of long-term administration of an anabolic steroid in intact and castrated male Wistar rats. Pharmacol. Biochem. Behav. 1993, 44:959-963.
70. Murphy D.L., Zohar J., Benkelfat C., Pato M.T., Pigott T.A., Insel T.R. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br. J. Psychiatry Suppl. 1989, 15-24.
71. Nelson R.J., Trainor B.C. Neural mechanisms of aggression. Nat. Rev. Neurosci. 2007, 8:536-546.
72. Newman M.G., Borkovec T.D., Hope D.A., Kozak M.J., McNally R.J., Taylor C.B. Future directions in the treatment of anxiety disorders: an examination of theory, basic science, public policy, psychotherapy research, clinical training, and practice. J. Clin. Psychol. 1999, 55:1325-1345.
73. NIDACapsules http://http//www.nida.nih.gov/NIDACapsules/NCIndex.html.
74. Nyberg J.M., Vekovischeva O., Sandnabba N.K. Anxiety profiles of mice selectively bred for intermale aggression. Behav. Genet. 2003, 33:503-511.
75. Ovsiukova M.V., Amikishieva A.V., Kaudriavtseva N.N., Obut T.A. Anxiolytic effect of dehydroepiandrosterone sulfate in male mice with high anxiety. Zh. Vyssh. Nerv. Deiat. Im. I P Pavlova 2003, 53:789-793.
76. Pagonis T.A., Angelopoulos N.V., Koukoulis G.N., Hadjichristodoulou C.S. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry 2006, 21:551-562.
77. Pagonis T.A., Angelopoulos N.V., Koukoulis G.N., Hadjichristodoulou C.S., Toli P.N. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur. Psychiatry 2006, 21:563-569.
78. Palleson S., Iosendal O., Johnsen B.H., Larsen S., Molde H. Anabolic steroid use in high school students. Subst. Use Misuse 2006, 41:1705-1717.
79. Parrilla-Carrero J., Figueroa O., Lugo A., Garcia-Sosa R., Brito-Vargas P., Cruz B., Rivera M., Barreto-Estrada J.L. The anabolic steroids testosterone propionate and nandrolone, but not 17alpha-methyltestosterone, induce conditioned place preference in adult mice. Drug Alcohol Depend. 2009, 100:122-127.
80. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 1986, 24:525-529.
81. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
82. Perry H.M., Hughes G.W. A case of affective disorder associated with the misuse of 'anabolic steroids'. Br. J. Sports Med. 1992, 26:219-220.
83. Perry P.J., Andersen K.H., Yates W.R. Illicit anabolic steroid use in athletes. A case series analysis. Am. J. Sports Med. 1990, 18:422-428.
84. Pohl R.B., Wolkow R.M., Clary C.M. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am. J. Psychiatry 1998, 155:1189-1195.
85. Pollack M.H., Otto M.W., Worthington J.J., Manfro G.G., Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch. Gen. Psychiatry 1998, 55:1010-1016.
86. Pollack M.H., Zaninelli R., Goddard A., McCafferty J.P., Bellew K.M., Burnham D.B., Iyengar M.K. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 2001, 62:350-357.
87. Pope H.G., Katz D.L. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch. Gen. Psychiatry 1994, 51:375-382.
88. Pope H.G., Katz D.L., Champoux R. Anabolic-androgenic steroid use among 1010 college men. Phys. Sports Med. 1988, 16:75-81.
89. Pope H.G., Kouri E.M., Powell K.F., Campbell C., Katz D.L. Anabolic-androgenic steroid use among 133 prisoners. Compr. Psychiatry 1996, 37:322-327.
90. Pratt J.A. The neuroanatomical basis of anxiety. Pharmacol. Ther. 1992, 55:149-181.
91. Rapaport M.H., Wolkow R., Rubin A., Hackett E., Pollack M., Ota K.Y. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr. Scand. 2001, 104:289-298.
92. Ricci L.A., Rasakham S., Grimes J.M., Melloni R.H. Serotonin 1A receptor activity and expression modulate adolescent anabolic/androgenic steroid induced aggression in hamsters. Pharmacol. Biochem. Behav. 2006, 85:1-11.
93. Rocha V.M., Calil C.M., Ferreira R., Moura M.J., Marcondes F.K. Influence of anabolic steroid on anxiety levels in sedentary male rats. Stress 2007, 10:326-331.
94. Rojas-Ortiz Y.A., Rundle-Gonzalez V., Rivera-Ramos I., Jorge J.C. Modulation of elevated plus maze behavior after chronic exposure to the anabolic steroid 17alpha-methyltestosterone in adult mice. Horm. Behav. 2006, 49:123-128.
95. Southwick S.M., Paige S., Morgan C.A., Bremner J.D., Krystal J.H., Charney D.S. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin. Clin. Neuropsychiatry 1999, 4:242-248.
96. Sprouse J., Braselton J., Reynolds L., Clarke T., Rollema H. Activation of postsynaptic 5-HT1A receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies. Synapse 2001, 41:49-57.
97. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998, 280:708-713.
98. Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993, 269:2760-2764.
99. Veenema A.H., Neumann I.D. Neurobiological mechanisms of aggression and stress coping: a comparative study in mouse and rat selection lines. Brain Behav. Evol. 2007, 70:274-285.
100. Veenema A.H., Torner L., Blume A., Beiderbeck D.I., Neumann I.D. Low inborn anxiety correlates with high intermale aggression: link to ACTH response and neuronal activation of the hypothalamic paraventricular nucleus. Horm. Behav. 2007, 51:11-19.
101. White M.P. Medication dosing in anxiety disorders: what the evidence shows. Prim. Psychiatry 2009, 16:21-28.
102. Williamson D.J. Anabolic steroid use among students at a British college of technology. Br. J. Sports Med. 1993, 27:200-201.
103. Williamson D.J. Misuse of anabolic drugs. BMJ 1993, 306:61.